Madrigal Pharma(MDGL.US)

Last Updated 19:00:00 ET
longbridge loading

What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders

Simplywall·
US
MDGL
+0.38%
US
LABU
+5.27%
US
FBT
+0.76%
Simplywall·
US
MDGL
+0.38%
US
LABU
+5.27%
US
FBT
+0.76%

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Unusual Whales·
US
MDGL
+0.38%
Unusual Whales·
US
MDGL
+0.38%

Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays

Tip Ranks·
US
MDGL
+0.38%
US
XBI
+1.73%
US
PBE
0.00%
Tip Ranks·
US
MDGL
+0.38%
US
XBI
+1.73%
US
PBE
0.00%

Bank of America Securities Sticks to Their Hold Rating for Madrigal Pharmaceuticals (MDGL)

Tip Ranks·
US
MDGL
+0.38%
US
SBIO
+1.63%
US
IBB
+0.89%
Tip Ranks·
US
MDGL
+0.38%
US
SBIO
+1.63%
US
IBB
+0.89%

<![CDATA[Pharmaceutical Executive Daily: Zentalis Doses First Patient with Azenosertib in Phase III Trial]]>

Pharmexec·
US
ZNTL
-0.42%
US
BAYRY
+1.45%
US
MDGL
+0.38%
Pharmexec·
US
ZNTL
-0.42%
US
BAYRY
+1.45%
US
MDGL
+0.38%

Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call

benzinga_article·
US
MDGL
+0.38%
US
ARKG
+1.44%
US
XBI
+1.73%
benzinga_article·
US
MDGL
+0.38%
US
ARKG
+1.44%
US
XBI
+1.73%

CVS Health shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY26 guidance.

benzinga_article·
US
CVS
+1.05%
benzinga_article·
US
CVS
+1.05%
© 2026 Longbridge｜Disclaimer